CoChat

Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients: Clinical value of ctDNA in metastatic pancreatic cancer

Open access
Cheng, He, Liu, Chen, Jiang, Jiahao, Luo, Guopei, Lu, Yu, Jin, Kaizhou, Guo, Meng, Zhang, Zhenzhen, Xu, Jin, Liu, Liang, Ni, Quanxing, Yu, Xianjun · 2017 · International Journal of Cancer
Cited by 145

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Cell-free circulating tumor DNA (ctDNA) in plasma has been used as a potential noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical implications of ctDNA detection in patients with metastatic pancreatic cancer. First, we attempted to prospectively screen a panel of 60 genes in cell-free DNA (cfDNA) from ten metastatic pancreatic cancer patients via exome sequencing. Second, droplet digital PCR (ddPCR) was used to identify potential mutations in a cohort of 188 patients with metastatic pancreatic cancer. Finally, to preliminary evaluate the potential role of ctDNA in monitoring tumor responses following chemotherapy, we detected the presence of ctDNA in serial plasma samples from 13 metastatic pancreatic cancer patients (Clinical trial: NCT02017015). The analysis revealed five somatic mutations at BRCA2, EGFR, KDR and ERBB2 gene loci. The frequencies of ctDNA mutation at BRCA2, KDR, EGFR, ERBB2 exon17 and ERBB2 exon27 were 11.7%, 13.8%, 13.3%, 13.3% and 6.4% respectively. Univariate and multivariate analyses identified the ERBB2 exon17 mutation (p = 0.035, HR = 1.61) as an independent factor associated with overall survival among metastatic pancreatic cancer patients. Furthermore, the rate of coincident detection of ctDNA and response to treatment as assessed by CT imaging was 76.9% (10 of 13 cases), and the presence of ctDNA provided the earliest measure of treatment in 6 of 10 patients (60%). ctDNA sequencing may have clinical value for determining metastatic pancreatic cancer treatment and monitoring the tumor response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.30650

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 145

Metadata

Authors
Cheng, H., Liu, C., Jiang, J., Luo, G., Lu, Y., Jin, K., Guo, M., Zhang, Z., Xu, J., Liu, L., Ni, Q., & Yu, X.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2017-03-09
Volume
140
Issue
10
Pages
2344-2350
ISSN
0020-7136 (ISSN-L)
OpenAlex
W2588225464
Cited by
145
References
10
FWCI
5.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients: Clinical value of ctDNA in metastatic pancreatic cancer. https://app.cochat.ai/papers/10.1002/ijc.30650
The paper
Cheng, H., Liu, C., Jiang, J., Luo, G., Lu, Y., Jin, K., Guo, M., Zhang, Z., Xu, J., Liu, L., Ni, Q., & Yu, X. (2017). Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients: Clinical value of ctDNA in metastatic pancreatic cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.30650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.